Only in Titles

           Search results for: AntiHuman   

paperclip

#28979173   2017/10/05 Save this To Up

Prevalence of RhD variants among blood donors at Gulu Regional Blood Bank, Gulu, Northern Uganda.

The aim of this study was to determine the prevalence of RhD variant phenotypes among voluntary non-remunerated blood donors (VNRBDs) at Gulu Regional Blood Bank (GRBB), Northern Uganda.

1480 related Products with: Prevalence of RhD variants among blood donors at Gulu Regional Blood Bank, Gulu, Northern Uganda.

REASTAIN® Quick Diff Kit anti A1, A2 human blood a anti A1, A2, A3 human blo anti B human blood antige anti AB human blood antig Blood Group Antibodies a anti B human blood group anti H n ab human blood a anti H ab human blood ant anti H inh human blood an anti M human blood antige anti N human blood antige

Related Pathways

paperclip

#28972064   2017/10/03 Save this To Up

Importance of Routine Antihuman/Leukocyte Antibody Monitoring: De Novo Donor Specific Antibodies Are Associated With Rejection and Allograft Vasculopathy After Heart Transplantation.


1791 related Products with: Importance of Routine Antihuman/Leukocyte Antibody Monitoring: De Novo Donor Specific Antibodies Are Associated With Rejection and Allograft Vasculopathy After Heart Transplantation.

Dengue Type 1 antibody, M Dengue Type 2 antibody, M Dengue Type 3 antibody, M Dengue Type 4 antibody, M Dengue antibody (Complex) PABP1-dependent poly A-sp Apoptosis antibody array Cell cycle antibody array Cytokine antibody array i Master antibody array is Signal transduction antib Angiogenesis (Human) Anti

Related Pathways

  •  
  • No related Items
paperclip

#28970677   2017/10/03 Save this To Up

Red cell alloimmunization in repeatedly transfused patients.

Repeated blood transfusions can result in the production of alloantibodies against one or more red cell antigens, which complicates subsequent transfusions. Aims: The study was done to find incidence of various red cell alloantibodies; to determine the type of alloantibody; to identify the factors such as frequency of transfusion, splenectomy status, donor ethnicity and gender and their association with the development of antibody in repeatedly transfused patients.

1085 related Products with: Red cell alloimmunization in repeatedly transfused patients.

Nile Red, A lipophilic dy Alamar Blue™, REDOX ind Alamar Blue™, REDOX ind anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl CELLKINES Natural Human I CELLKINES INTERLEUKIN 2 ( CELLKINES INTERLEUKIN 2 ( Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu

Related Pathways

paperclip

#28955989   2017/09/28 Save this To Up

De novo protein sequencing, humanization and in vitro effects of an antihuman CD34 mouse monoclonal antibody.

QBEND/10 is a mouse immunoglobulin lambda-chain monoclonal antibody with strict specificity against human hematopoietic progenitor cell antigen CD34. Our in vitro study showed that QBEND/10 impairs the tube formation of human umbilical vein endothelial cells (HUVECs), suggesting that the antibody may be of potential benefit in blocking tumor angiogenesis. We provided a de novo protein sequencing method through tandem mass spectrometry to identify the amino acid sequences in the variable heavy and light chains of QBEND/10. To reduce immunogenicity for clinical applications, QBEND/10 was further humanized using the resurfacing approach. We demonstrate that the de novo sequenced and humanized QBEND/10 retains the biological functions of the parental mouse counterpart, including the binding kinetics to CD34 and blockage of the tube formation of the HUVECs.

1255 related Products with: De novo protein sequencing, humanization and in vitro effects of an antihuman CD34 mouse monoclonal antibody.

Rabbit Anti-Cell death in Rabbit Anti-Cell death in Monoclonal Anti-Death Ass Anti AGO2 Mouse, Monoclon Anti AGO2 Mouse, Monoclon HIV1 integrase antibody, Dengue Type 1 antibody, M Dengue Type 2 antibody, M Dengue Type 3 antibody, M Dengue Type 4 antibody, M Dengue antibody (Complex) Anti CEL Monoclonal Antib

Related Pathways

paperclip

#28939747   2017/09/23 Save this To Up

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a unique anti-GD2 mAb, hu14.18K322A, combined with chemotherapy, cytokines, and haploidentical natural killer (NK) cells.Experimental Design: Children with recurrent/refractory neuroblastoma received up to six courses of hu14.18K322A (40 mg/m(2)/dose, days 2-5), GM-CSF, and IL2 with chemotherapy: cyclophosphamide/topotecan (courses 1,2), irinotecan/temozolomide (courses 3,4), and ifosfamide/carboplatin/etoposide (courses 5,6). Parentally derived NK cells were administered with courses 2, 4, and 6. Serum for pharmacokinetic studies of hu14.18K322A, soluble IL2 receptor alpha (sIL2Rα) levels, and human antihuman antibodies (HAHA) were obtained.Results: Thirteen heavily pretreated patients (9 with prior anti-GD2 therapy) completed 65 courses. One patient developed an unacceptable toxicity (grade 4 thrombocytopenia >35 days). Four patients discontinued treatment for adverse events (hu14.18K322A allergic reaction, viral infection, surgical death, second malignancy). Common toxicities included grade 3/4 myelosuppression (13/13 patients) and grade 1/2 pain (13/13 patients). Eleven patients received 29 NK-cell infusions. The response rate was 61.5% (4 complete responses, 1 very good partial response, 3 partial responses) and five had stable disease. The median time to progression was 274 days (range, 239-568 days); 10 of 13 patients (77%) survived 1 year. Hu14.18K322A pharmacokinetics was not affected by chemotherapy or HAHA. All patients had increased sIL2Rα levels, indicating immune activation.Conclusions: Chemotherapy plus hu14.18K322A, cytokines, and NK cells is feasible and resulted in clinically meaningful responses in patients with refractory/recurrent neuroblastoma. Further studies of this approach are warranted in patients with relapsed and newly diagnosed neuroblastoma. Clin Cancer Res; 1-9. ©2017 AACR.

2867 related Products with: A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

Anti C Reactive Protein A Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl Anti 3 DG imidazolone Mon Mouse Anti-Insulin(1G11) Mouse Anti-Insulin(1G11) Mouse Anti-Insulin(1G11)

Related Pathways

paperclip

#28874644   2017/09/06 Save this To Up

Immunohistochemical Expression of Cathepsin D in Primary and Recurrent Squamous Cell Carcinoma.

The aim of this study is to analyze and compare the immunohistochemical expression of cathepsin B in primary oral squamous cell carcinoma (OSCC) and recurrent OSCC.

1618 related Products with: Immunohistochemical Expression of Cathepsin D in Primary and Recurrent Squamous Cell Carcinoma.

Oral cavity squamous cell Lung squamous cell carcin Cervix squamous cell carc Esophagus squamous cell c Esophagus squamous cell c Esophageal squamous cell Esophagus squamous cell c Esophageal squamous cell High density non small ce Skin squamous cell carcin DNA (cytosine 5) methyltr Macrophage Colony Stimula

Related Pathways

paperclip

#28871249   2017/09/05 Save this To Up

Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine-Nanobody Complex.

The heterodimeric cytokine interleukin (IL) 23 comprises the IL12-shared p40 subunit and an IL23-specific subunit, p19. Together with IL12 and IL27, IL23 sits at the apex of the regulatory mechanisms shaping adaptive immune responses. IL23, together with IL17, plays an important role in the development of chronic inflammation and autoimmune inflammatory diseases. In this context, we generated monovalent antihuman IL23 variable heavy chain domain of llama heavy chain antibody (VHH) domains (Nanobodies(®)) with low nanomolar affinity for human interleukin (hIL) 23. The crystal structure of a quaternary complex assembling hIL23 and several nanobodies against p19 and p40 subunits allowed identification of distinct epitopes and enabled rational design of a multivalent IL23-specific blocking nanobody. Taking advantage of the ease of nanobody formatting, multivalent IL23 nanobodies were assembled with properly designed linkers flanking an antihuman serum albumin nanobody, with improved hIL23 neutralization capacity in vitro and in vivo, as compared to the monovalent nanobodies. These constructs with long exposure time are excellent candidates for further developments targeting Crohn's disease, rheumatoid arthritis, and psoriasis.

1738 related Products with: Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine-Nanobody Complex.

Cytokine (Human) Antibody Anti AGO2 Human, Monoclon Anti AGO2 Human, Monoclon CELLKINES Natural Human I Human Interleukin-4 IL-4 Human Interleukin-6 IL-6 Human Interleukin-7 IL-7 Human Interleukin-2 IL-2 Human Interleukin-16 IL-1 Human Interleukin-33 IL-3 Human Interleukin-17E (IL Human Interleukin-32 alph

Related Pathways

  •  
  • No related Items
paperclip

#28729851   2017/07/21 Save this To Up

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

To develop and validate a method for the detection of binding anti-drug antibodies (ADAs) against interferon beta (IFN-β) in human serum as part of a European initiative (ABIRISK) aimed at the prediction and analysis of clinical relevance of anti-biopharmaceutical immunization to minimize the risk.

2734 related Products with: Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

Rabbit Anti-Rat Androgen Rat monoclonal anti mouse Mouse Anti-Human CG beta Mouse Anti-Human CG beta Mouse Anti-Human IFN-beta Mouse Anti-Human IFN-beta Mouse Anti-Human IL-1 bet Mouse Anti-Human IL-1 bet Mouse Anti-Human MIP-3 be Mouse Anti-Human MIP-3 be Rat Anti-Mouse TCR V beta Rat Anti-Mouse TCR V beta

Related Pathways

paperclip

#28682067   2017/07/06 Save this To Up

Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.

Acyclic nucleosides containing a 3-fluoro-2-(phosphonomethoxy)propyl (FPMP) side chain are known to be moderately potent antihuman immunodeficiency virus (HIV) agents, while being completely devoid of antiviral activity against a wide range of DNA viruses. The derivatization of the phosphonic acid functionality of FPMPs with a diamyl aspartate phenoxyamidate group led to a novel generation of compounds that not only demonstrate drastically improved antiretroviral potency but also are characterized by an expanded spectrum of activity that also covers hepatitis B and herpes viruses. The best compound, the (S)-FPMPA amidate prodrug, exerts anti-HIV-1 activity in TZM-bl and peripheral blood mononuclear cells at low nanomolar concentrations and displays excellent potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV). This prodrug is stable in acid and human plasma media, but it is efficiently processed in human liver microsomes with a half-life of 2 min. The (R) isomeric guanine derivative emerged as a selectively active anti-HIV and anti-HBV inhibitor, while being nontoxic to human hepatoblastoma cells. Notably, the pyrimidine containing prodrug (S)-Asp-FPMPC is the only congener within this series to demonstrate micromolar antihuman cytomegalovirus (HCMV) potency.

2479 related Products with: Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.

BACTERIOLOGY BACTEROIDES Amplite™ Fluorimetric A Amplite™ Colorimetric A Oxonol VI [Bis (3 propyl TCP-1 theta antibody Sour Recombinant Thermostable Recombinant Thermostable Recombinant Thermostable Recombinant Human PKC the Recombinant Human PKC the Recombinant Human PKC the Single Strand DNA Ligase,

Related Pathways

paperclip

#28656253   2017/06/28 Save this To Up

Heat shock protein 90β in the Vero cell membrane binds Japanese encephalitis virus.

The pathogenesis of Japanese encephalitis virus (JEV) is complex and unclearly defined, and in particular, the effects of the JEV receptor (JEVR) on diverse susceptible cells are elusive. In contrast to previous studies investigating JEVR in rodent or mosquito cells, in this study, we used primate Vero cells instead. We noted that few novel proteins co‑immunoprecipitated with JEV, and discovered that one of these was heat shock protein 90β (HSP90β), which was probed by mass spectrometry with the highest score of 60.3 after questing the monkey and human protein databases. The specific HSP90β‑JEV binding was confirmed by western blot analysis under non‑reducing conditions, and this was significantly inhibited by an anti‑human HSP90β monoclonal antibody in a dose‑dependent manner, as shown by immunofluorescence assay and flow cytometry. In addition, the results of confocal laser scanning microscopic examination demonstrated that the HSP90β‑JEV binding occurred on the Vero cell surface. Finally, JEV progeny yields determined by plaque assay were also markedly decreased in siRNA‑treated Vero cells, particularly at 24 and 36 h post‑infection. Thus, our data indicate that HSP90β is a binding receptor for JEV in Vero cells.

2098 related Products with: Heat shock protein 90β in the Vero cell membrane binds Japanese encephalitis virus.

Octyl â D 1 thioglucopyr Heat Shock Protein 70 (H Heat Shock Protein 70 (H Recombinant Japanese Ence Recombinant Japanese Ence Recombinant Japanese Ence Heat Shock Protein 20, hu Heat Shock Protein 22, hu Heat Shock Protein 27, hu Heat Shock Protein 65, my Heat Shock Protein 90, hu Heat Shock Protein 70, hu

Related Pathways